What is the price target for CRVS stock?
13 analysts have analysed CRVS and the average price target is 35.7 USD. This implies a price increase of 153.64% is expected in the next year compared to the current price of 14.075.
CORVUS PHARMACEUTICALS INC (CRVS) Forecast, Price Target & Analyst Ratings
NASDAQ:CRVS • US2210151005
Current stock price
14.075 USD
-0.15 (-1.02%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CORVUS PHARMACEUTICALS INC (CRVS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.14
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$35.70
Upside
+ 153.64%
From current price of $14.08 to mean target of $35.70, Based on 13 analyst forecasts
Low
$27.27
Median
$31.62
High
$53.55
Price Target Revisions
1 Month
0.00%
3 Months
128.26%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for CRVS. The average price target is 35.7 USD. This implies a price increase of 153.64% is expected in the next year compared to the current price of 14.075.
The average price target has been revised upward by 128.26% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.15%
CRVS was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CRVS.
In the previous month the buy percentage consensus was at a similar level.
CRVS was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2026-01-22 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-21 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-05-20 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-03-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-16 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-05-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-03-27 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-16 | Mizuho | Reiterate | Neutral -> Neutral |
| 2023-05-30 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-05-09 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2022-10-07 | Ladenburg Thalmann | Initiate | Buy |
| 2021-12-03 | Cantor Fitzgerald | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.14
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -168.69%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-2.12%
EPS (3 Months)
-2.12%
Next Earnings Summary
CRVS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 214.16% | N/A 142.47% | N/A 111.64% | N/A 131.04% | N/A 69.00% | N/A 14.47% | ||||||||||||
| EBITDA YoY % growth | -13.62M | -36.39M -167.18% | -55.68M -53.01% | -48.37M 13.13% | -48.11M 0.54% | -43.13M 10.35% | -38.17M 11.50% | -32.2M 15.64% | -23.256M 27.78% | -27.463M -18.09% | -42.866M -56.09% | N/A -18.98% | N/A -30.00% | N/A 138.77% | N/A 347.63% | N/A 121.18% | N/A 33.75% | N/A 72.16% | N/A 16.87% | |
| EBIT YoY % growth | -13.77M | -36.98M -168.55% | -56.52M -52.84% | -49.22M 12.92% | -48.85M 0.75% | -43.76M 10.42% | -38.63M 11.72% | -32.57M 15.69% | -23.407M 28.13% | -27.548M -17.69% | -42.971M -55.99% | N/A -48.64% | N/A -10.84% | N/A 21.49% | N/A 93.26% | N/A 2,017.30% | N/A 272.08% | N/A 110.23% | N/A 70.84% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -6.88 | -2.72 60.47% | -1.75 35.66% | -1.59 9.14% | -1.46 8.18% | -1.06 27.40% | -0.89 16.04% | -0.57 35.96% | -0.94 -64.91% | -0.16 82.98% | N/A -284.60% | N/A -21.00% | N/A 73.05% | N/A 155.92% | N/A 857.55% | N/A 130.70% | N/A 65.84% | N/A 75.81% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 -168.69% | -0.14 -36.68% | -0.15 -21.41% | -0.16 -8.68% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.734M -38.42% | -14.224M -38.64% | -15.43M -45.95% | -17.395M -42.39% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-7.84%
EPS Next 5 Year
54.19%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
37.64%
EBIT Next 5 Year
51.64%
CORVUS PHARMACEUTICALS INC / CRVS Forecast FAQ
Can you provide the upcoming earnings date for CORVUS PHARMACEUTICALS INC?
CORVUS PHARMACEUTICALS INC (CRVS) will report earnings on 2026-05-06.
Can you provide the consensus estimates for CORVUS PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of CORVUS PHARMACEUTICALS INC (CRVS) is -0.14 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for CRVS stock?
The consensus rating for CORVUS PHARMACEUTICALS INC (CRVS) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.